Form 4: Integra LifeSciences Director Acquires Shares

Barbara B. Hill, a Director at Integra LifeSciences Holdings Corp. (IART), reported the acquisition of 6,638 and 17,700 shares of common stock on May 7, 2026.

Summary

• Barbara B. Hill, a Director of Integra LifeSciences Holdings Corp. (IART), has reported transactions involving the acquisition of company stock.
• On May 7, 2026, Ms. Hill acquired 6,638 shares of common stock directly, with no cost indicated (likely a grant or award).
• On the same date, Ms. Hill acquired an additional 17,700 shares of common stock directly, also with no cost indicated.
• Following these transactions, Ms. Hill beneficially owns 133,491 shares directly and 151,191 shares directly.
• Additionally, Ms. Hill beneficially owns 36,350 shares indirectly through a trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as director stock acquisitions can signal confidence, but the lack of transaction price and details on the nature of the acquisition limit a more definitive positive assessment.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• The acquisition of a significant number of shares (24,338 total) by a director may be viewed positively by the market.
• Ms. Hill's direct ownership of a substantial number of shares (151,191) indicates a strong personal investment in the company.

Negatives

• The filing does not provide the purchase price for the acquired shares, making it difficult to assess the financial commitment or perceived value by the director.
• The indirect ownership through a trust could obscure the ultimate beneficial owner's intentions or control.

Risks

• The nature of the acquisition (e.g., stock grant, option exercise, open market purchase) is not explicitly detailed, which could influence the interpretation of the transaction's intent.
• While not explicitly stated as a risk in this filing, any significant insider selling following such acquisitions could be viewed negatively.

Future Outlook

This filing is a statement of changes in beneficial ownership and does not contain forward-looking statements or guidance regarding future financial performance.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director of Integra LifeSciences, are closely watched by investors as potential indicators of management's confidence in the company's performance and future prospects within the life sciences industry.

Stakeholder Impact

• Shareholders: May interpret the director's stock acquisition as a positive signal of confidence in the company's future, potentially influencing investment decisions.
• Employees: May view the director's increased stake as a sign of stability and commitment from leadership.
• Creditors: Unlikely to be directly impacted by this transaction.

Next Steps

• Continued monitoring of insider transactions for any further activity by Barbara B. Hill or other executives at Integra LifeSciences.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Beneficial Ownership, Stock Acquisition, Director, Integra LifeSciences, IART, Securities Exchange Act, Rule 10b5-1